Liver Disease Clinical Trials

Showing 1241-1260 of 1,498 trials

The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers

NCT02415348

This study is designed to determine if the Fibroscan (Echosens, Paris), a non-invasive, ultrasound-based device used to estimate fibrosis in patients with chronic liver disease, interferes with implanted cardiac pacemaker and/or implantable cardioverter-defibrillators. Recruitment consists of a total of 200 outpatients undergoing routine pacemaker interrogation at a teaching-hospital pacemaker clinic.

Liver Cirrhosis

University of Saskatchewan200 participantsStarted Apr 2015

Saskatoon, Saskatchewan, Canada

UNKNOWN

Meta-analyses of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk

NCT02702479

The rise in high fructose corn syrup (HFCS) consumption over the past 40 years since its introduction as a popular sweetener in the United States has led to much concern regarding its contribution to the rise in obesity (1), diabetes (2) and related cardiometabolic disorders (3).Unlike sucrose which contains equal proportions of fructose and glucose bound by an α-glycosidic bond, HFCS contains 42-55% of fructose to glucose in a free (unbound) form (4). Despite these differences in composition, both sugars possess identical energy contribution on a gram to gram basis (4). However, the higher ratio of fructose to glucose in HFCS has led to the hypothesis that HFCS may uniquely contribute to cardiometabolic risk, more so than sucrose, through proposed differences in fructose metabolism, endocrine and hedonic properties (5). We will conduct a series of systematic reviews and meta-analyses to assess the role of HFCS versus sucrose under energy matched (isocaloric) conditions on cardiometabolic risk.

ObesityDyslipidemiaPrediabetes+5 more

University of Toronto1 participantsStarted Jun 2014

Toronto, Ontario, Canada

The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers

Meta-analyses of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk

Related Searches

Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease

Fatty Acids, Genes and Microbiota in Fatty Liver

Evaluation of EV1000™/volumeView™ for Cardiac Output Monitoring in Liver Transplantation

Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates

Influence of Probiotics on Infections in Cirrhosis

The Establishment of Multiple Point Prediction Model About Tacrolimus Metabolic Differences Based on Genetic Network After Liver Transplantation and the Application of Multicenter

Comparison of Standard Dose Versus Once a Day Intravenous Albumin in Spontaneous Bacterial Peritonitis

Hepatic Fibrosis Non-invasive Methods Questionnaire

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis

REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)

An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension

The Use of Transient Elastography to Predict Clinical Decompensation in Patients With Early Cirrhosis

Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation

Cirrhosis, Effects of TRAnsplantation and Diabetes

The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding

PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers

Mesenchymal Stem Cells Treat Liver Cirrhosis